947673-12-3

Basic information

• Product Name: 1-Piperazinecarboxylic acid, 4-(4-aMinophenyl)-, phenylMethyl ester
• Synonyms: 1-Piperazinecarboxylic acid, 4-(4-aMinophenyl)-, phenylMethyl ester;Benzyl 4-(4-aminophenyl)piperazine-1-carboxylate;1-(4-Amino-phenyl)-4-Cbz-piperazine
• CAS NO: 947673-12-3
• Molecular Formula: C₁₈H₂₁N₃O₂
• Molecular Weight: 311.37824
• Mol File: 947673-12-3.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Piperazinecarboxylic acid, 4-(4-aMinophenyl)-, phenylMethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperazinecarboxylic acid, 4-(4-aMinophenyl)-, phenylMethyl ester(947673-12-3)
• EPA Substance Registry System: 1-Piperazinecarboxylic acid, 4-(4-aMinophenyl)-, phenylMethyl ester(947673-12-3)

Safety Data

• Hazardous Substances Data: 947673-12-3(Hazardous Substances Data)

Usage

Type of compound

chemical compound, derivative of piperazine

Functional group

phenylmethyl ester

Uses

pharmaceutical research, building block in the synthesis of various organic compounds, production of several pharmaceutical drugs, preparation of various heterocyclic compounds

Medicinal properties

potential affinity for certain receptors in the brain

Importance

considered an important intermediate in the production of several pharmaceutical drugs

Upstream product

• 350-46-9 4-Fluoronitrobenzene 
• 6269-89-2 1-(4-Nitrophenyl)piperazine 
• 501-53-1 benzyl chloroformate 
• 67455-41-8 4-(piperazin-1-yl)aniline 
• 947673-13-4 benzyl 4-(4-nitrophenyl)piperazine-1-carboxylate 

Downstream Products

• 1092542-97-6 C₂₈H₂₈Cl₂N₆O 
• 1092542-99-8 C₂₈H₂₉ClN₆O 
• 1092543-00-4 C₂₉H₃₂N₆O 
• 1092067-38-3 C₂₇H₂₈Cl₂N₄OS 
• 1092070-00-2 CH₄O₃S*C₃₁H₃₅Cl₂N₅O₃ 
• 1092068-34-2 C₃₂H₃₈Cl₂N₆O₅S 
• 1092068-66-0 C₃₁H₃₅Cl₂N₅O₄ 
• 1092068-68-2 C₃₁H₃₅Cl₂N₅O₅ 
• 1092067-85-0 N-[2,6-dichloro-4-(pyrrolidin-1-ylmethyl)phenyl]4-(4-{[(4-methoxyphenyl)-acetyl]amino}phenyl)piperazine-1-carboxamide 
• 1092065-41-2 C₂₈H₂₇Cl₂F₃N₄O₃ 
• 1092069-94-7 C₃₂H₃₇ClN₄O₅ 
• 1092069-34-5 CH₄O₃S*C₁₉H₂₃N₃O₂ 
• 1092065-40-1 C₂₉H₃₁ClN₄O₃ 
• 1092065-39-8 C₂₉H₃₃BrN₄O₂ 

Relevant articles and documents

FUSED PYRIMIDINE PYRIDINONE COMPOUNDS AS JAK INHIBITORS

The disclosure provides compounds of formula (I), or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The disclosure also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal inflammatory diseases.

VEGFR3 INHIBITORS

This invention relates to compounds of the formula (I). The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphanglogenesis.

PIPERIDINE/PIPERAZINE DERIVATIVES

The invention relates to a DGAT inhibitor of formula (I): including any stereochemically isomeric form thereof, wherein A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X represents -C(=O)-; -O-C(=O)-; -C(=O)-C(=O)-; -NRx-C(=O)-; -Z1-C(O)-; -Z1-NRx-C(=O)-; -C(=O)-Z1-; -NRx-C(=O)-Z1-; -S(=O)p-; -C(=S)-; -NRx-C(=S)-; -Z1-C(=S)-; -Z1-NRX-C(=S)-; -C(=S)-Z1-; -NRx-C(=S)-Z1-; Y represents NRx-C(=0)- Z2-; -NRx-C(=0)-Z2-NRy-; -NRx-C(=0)-Z2-NRy-C(=0)-; -NRx-C(=0)-Z2-NRy-C(=0)- O-; -NRx-C(=0)-Z2-0-; -NRx-C(=0)-Z2-0-C(=0)-; -NRx-C(=0)-Z2-C(=0)-; -NRx-C(=0)-Z2-C(=0)-0-; -NRx-C(=0)-0-Z2-C(=0)-; -NRx-C(=0)-0-Z2-C(=0)-0-; -NRx-C(=O)-O-Z2-O-C(=O)-; -NRx-C(=O)-Z2-C(=O)-NRy-; -NRx-C(=O)-Z2-NRy- C(=0)-NRy-; -C(=O)-Z2-; -C(=O)-Z2-O-; -C(=0)-NRx-Z2-; -C(=0)-NRx-Z2-0-; -C(=0)-NRx-Z2-C(=0)-0-; -C(=0)-NRx-Z2-0-C(=0)-; -C(=0)-NRx-0-Z2-; -C(=O)- NRx-Z2-NRy-; -C(=0)-NRx-Z2-NRy-C(=0)-; -C(=0)-NRx-Z2-NRy-C(=0)-0-; R1 represents C1-12alkyl optionally substituted with cyano, C1-4alkyloxy, C1-4alkyl-oxyC1-4alkyloxy, C3-6Cy cloalkyl or aryl; C2-6alkenyl; C2-6alkynyl; C3-6cycloalkyl; adamantanyl; aryl1; aryl1C1-6alkyl; Het1; or Het1C1-6alkyl; provided that when Y represents -NRX-C(=O)-Z2-; -NRx-C(=0)-Z2-NRy; -NRX-C(=O)-Z2-C(=O)- NRy-; -C(=O)-Z2-; -NRx-C(=0)-Z2-NRy-C(=0)-NRy-; -C(=O)-NRX-Z2-; -C(=O)-NRX- O-Z2-; or -C(=0)-NRx-Z2-NRy-; then R1 may also represent hydrogen; R2 represents hydrogen, C1-12alkyl, C2-6alkenyl or R3; provided that if X represents -O-C(=O)-, then R2 represents R3; and provided that is excluded; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds.